Cyclo Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Rafael Holdings finalizes its merger with Cyclo Therapeutics, issuing shares and warrants, and focusing on the TransportNPC trial for Niemann-Pick Disease Type C1.
Cyclo Therapeutics stockholders voted to approve the merger agreement with Rafael Holdings at a special meeting held on March 20, 2025.
Cyclo Therapeutics entered into a Ninth Amended and Restated Note Purchase Agreement with Rafael Holdings, issuing a $2.5 million convertible promissory note.
Cyclo Therapeutics extends its merger agreement deadline with Rafael Holdings to March 31, 2025, and secures an additional $2 million in convertible promissory notes from Rafael.
Cyclo Therapeutics received a notice from Nasdaq for failing to hold its annual shareholder meeting within the required timeframe, potentially leading to delisting.
Cyclo Therapeutics has entered into a seventh amended agreement with Rafael Holdings, securing a $3 million convertible promissory note to be used for working capital and general corporate purposes.
Cyclo Therapeutics and Rafael Holdings have extended the deadline for their merger agreement and the maturity dates of convertible promissory notes to February 15, 2025.
Cyclo Therapeutics has entered into a sixth amended agreement with Rafael Holdings, issuing a $1 million convertible promissory note to support working capital and general corporate purposes.
Cyclo Therapeutics has entered into a fifth amended agreement with Rafael Holdings, issuing a $2 million convertible promissory note to support working capital and general corporate purposes.
8-K: Cyclo Therapeutics Faces Nasdaq Delisting Threat After Failing to Meet Minimum Listing Requirements
Cyclo Therapeutics has received notification from Nasdaq that it is not in compliance with several listing rules, including minimum share price, stockholders' equity, market value, and net income requirements, placing the company at risk of delisting.
8-K: Cyclo Therapeutics Secures $3 Million in Convertible Debt, Amends Prior Notes with Rafael Holdings
Cyclo Therapeutics has entered into a fourth amended agreement with Rafael Holdings, issuing a $3 million convertible note and amending previous notes to mature on December 21, 2024, with a potential merger on the horizon.
8-K: Cyclo Therapeutics Secures $3 Million in Convertible Debt from Rafael Holdings Amidst Merger Plans
Cyclo Therapeutics has entered into a third amended agreement with Rafael Holdings, securing a $3 million convertible promissory note, while a merger between the two companies is pending.
Rafael Holdings and Cyclo Therapeutics have agreed to merge, focusing on the development of Trappsol Cyclo for Niemann-Pick Disease Type C1.
Cyclo Therapeutics has entered into an amended agreement with Rafael Holdings, issuing a $2 million convertible promissory note to bolster working capital.
Cyclo Therapeutics has entered into a $2 million convertible note agreement with Rafael Holdings to bolster working capital and general corporate operations.
Cyclo Therapeutics has filed an amended 8-K report to include additional financial information related to its merger with Applied Molecular Transport, which was completed on December 27, 2023.
Cyclo Therapeutics has received notification from Nasdaq that it has regained compliance with listing standards, leading to the cancellation of a scheduled hearing.